126 related articles for article (PubMed ID: 14698546)
1. Reply to "Radiation pneumonitis and docetaxel".
Senan S
Lung Cancer; 2004 Jan; 43(1):117-8; author reply 119-20. PubMed ID: 14698546
[No Abstract] [Full Text] [Related]
2. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis.
Onishi H; Kuriyama K; Yamaguchi M; Komiyama T; Tanaka S; Araki T; Nishikawa K; Ishihara H
Lung Cancer; 2003 Apr; 40(1):79-84. PubMed ID: 12660011
[TBL] [Abstract][Full Text] [Related]
3. Two-dimensional radiotherapy and docetaxel in treatment of stage III non-small cell lung carcinoma: no good survival due to radiation pneumonitis.
Dinçbas FO; Atalar B; Koca S
Lung Cancer; 2004 Feb; 43(2):241-2. PubMed ID: 14739045
[No Abstract] [Full Text] [Related]
4. Preoperative concurrent radiation therapy and cisplatinum continuous infusion in IIIa (N2) non small cell lung cancer. A pilot study.
Maggi G; Casadio C; Cianci R; Oliaro A; Molinatti M; Bretti S; Clerico M; Boidi-Trotti A; Rovea P
J Cardiovasc Surg (Torino); 1994 Aug; 35(4):341-6. PubMed ID: 7929550
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
Jain AK; Hughes RS; Sandler AB; Dowlati A; Schwartzberg LS; Dobbs T; Schlabach L; Wu J; Muldowney NJ; Choy H
J Thorac Oncol; 2009 Jun; 4(6):722-7. PubMed ID: 19404213
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
Gadgeel SM; Ruckdeschel JC; Patel BB; Wozniak A; Konski A; Valdivieso M; Hackstock D; Chen W; Belzer K; Burger AM; Marquette L; Turrisi A
J Thorac Oncol; 2011 May; 6(5):927-33. PubMed ID: 21415776
[TBL] [Abstract][Full Text] [Related]
7. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.
Werner-Wasik M; Scott C; Graham ML; Smith C; Byhardt RW; Roach M; Andras EJ
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):327-31. PubMed ID: 10760427
[TBL] [Abstract][Full Text] [Related]
8. Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer.
Font A; Arellano A; Fernández-Llamazares J; Casas D; Boix J; Cardenal J; Margelí M; Manzano JL; Abad A; Rosell R
Clin Transl Oncol; 2007 Mar; 9(3):177-82. PubMed ID: 17403629
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma.
Le Chevalier T; Arriagada R; Quoix E; Ruffie P; Martin M; Douillard JY; Tarayre M; Lacombe-Terrier MJ; Laplanche A
Lung Cancer; 1994 Mar; 10 Suppl 1():S239-44. PubMed ID: 8087515
[TBL] [Abstract][Full Text] [Related]
10. Effect of Increased Radiotoxicity on Survival of Patients with Non-small Cell Lung Cancer Treated with Curatively Intended Radiotherapy.
Holgersson G; Bergström S; Liv P; Nilsson J; Edlund P; Blomberg C; Nyman J; Friesland S; Ekman S; Asklund T; Henriksson R; Bergqvist M
Anticancer Res; 2015 Oct; 35(10):5491-7. PubMed ID: 26408714
[TBL] [Abstract][Full Text] [Related]
11. Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction.
Chhajed PN; Baty F; Pless M; Somandin S; Tamm M; Brutsche MH
Chest; 2006 Dec; 130(6):1803-7. PubMed ID: 17167000
[TBL] [Abstract][Full Text] [Related]
12. Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma.
Koukourakis MI; Bahlitzanakis N; Froudarakis M; Giatromanolaki A; Georgoulias V; Koumiotaki S; Christodoulou M; Kyrias G; Skarlatos J; Kostantelos J; Beroukas K
Br J Cancer; 1999 Aug; 80(11):1792-6. PubMed ID: 10468298
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.
Weiss GJ; Vokes EE; Bunn PA; Magree L; Rusk J; Albert D; Kelly K
J Thorac Oncol; 2007 Oct; 2(10):933-8. PubMed ID: 17909356
[TBL] [Abstract][Full Text] [Related]
14. A study of ethnic differences in TGFβ1 gene polymorphisms and effects on the risk of radiation pneumonitis in non-small-cell lung cancer.
Niu X; Li H; Chen Z; Liu Y; Kan M; Zhou D; Li Z; Ye X; Shen S; Lv C; Lu S
J Thorac Oncol; 2012 Nov; 7(11):1668-75. PubMed ID: 23059779
[TBL] [Abstract][Full Text] [Related]
15. Time to treatment in patients with stage III non-small cell lung cancer.
Wang L; Correa CR; Hayman JA; Zhao L; Cease K; Brenner D; Arenberg D; Curtis J; Kalemkerian GP; Kong FM
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):790-5. PubMed ID: 19231108
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin plus epirubicin and etoposide followed by irradiation plus lonidamine in stage III nonsmall cell lung cancer.
Filipazzi V; Cattaneo MT; Rho B; Frontini L; D'Adda D; Isa L; Scapaticci R; Legnani W; Calzavara MP; Berni F
Oncology; 1993; 50(1):10-3. PubMed ID: 8380632
[TBL] [Abstract][Full Text] [Related]
17. Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
Fujimoto N; Kiura K; Takigawa N; Fujiwara Y; Toyooka S; Umemura S; Tabata M; Ueoka H; Tanimoto M
Acta Med Okayama; 2010 Feb; 64(1):33-7. PubMed ID: 20200582
[TBL] [Abstract][Full Text] [Related]
18. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.
Komaki R; Scott CB; Sause WT; Johnson DH; Taylor SG; Lee JS; Emami B; Byhardt RW; Curran WJ; Dar AR; Cox JD
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):537-44. PubMed ID: 9336129
[TBL] [Abstract][Full Text] [Related]
19. A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.
Kotsakis A; Matikas A; Koinis F; Kentepozidis N; Varthalitis II; Karavassilis V; Samantas E; Katsaounis P; Dermitzaki EK; Hatzidaki D; Mavroudis D; Georgoulias V
Br J Cancer; 2016 Sep; 115(7):784-8. PubMed ID: 27607471
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.
Dilling TJ; Extermann M; Kim J; Thompson LM; Yue B; Stevens CW; Antonia S; Gray J; Williams C; Haura E; Pinder-Schenck M; Tanvetyanon T; Kim S; Chiappori A
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):828-33. PubMed ID: 25216856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
